T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis.
Resource Type
Report
Authors
Fang H; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Beird HC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Ibrahim AF; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, USA.; Tang Z; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; You MJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Hu S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Xu J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Li S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Yin CC; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; El Hussein S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Le N; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Futreal PA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Bueso-Ramos C; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Thakral B; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Thornton R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Little L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Gumbs C; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Wang W; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. wwang13@mdanderson.org.
Source
Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE